Free Trial
→ The investigation Porter spent tens of thousands to document (From Porter & Company) (Ad)tc pixel Free VIR Stock Alerts

Vir Biotechnology (VIR) News Today

Vir Biotechnology logo
$13.13 -0.02 (-0.15%)
Closing price 04:00 PM Eastern
Extended Trading
$13.12 -0.01 (-0.04%)
As of 04:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

Why Is Vir Biotechnology Down Today?

Vir Biotechnology, Inc. (NASDAQ: VIR) has several positive analyst and clinical-trial catalysts, while questions about valuation after a sharp rally may temper sentiment.

  • Positive Sentiment: Vir’s hepatitis D combination therapy met all primary endpoints in its Phase 3 trial, and the company also reported encouraging Phase 2 and expanded-trial data. The results strengthen the case for its hepatitis D program. Vir’s combo approach nails Phase III endpoints in hepatitis D trial
  • Positive Sentiment: Morgan Stanley raised its price target to $28 from $25 and maintained an Overweight rating. HC Wainwright also reiterated its Buy rating and $22 target, while raising its 2026 and 2027 earnings estimates, signaling expectations for smaller losses than previously forecast. Vir Biotechnology analyst estimates and ratings
  • Neutral Sentiment: A recent article asks whether VIR is overvalued after a 127% run. That valuation concern could limit enthusiasm, although the article’s headline alone does not establish its conclusion. Is Vir Biotechnology (VIR) Overvalued After Its 127% Run?
Posted 1h agoAI Generated. May Contain Errors.

Vir Biotechnology Latest News

Is Vir Biotechnology (VIR) Overvalued After Its 127% Run?
 |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/vir-biotechnology-vir-overvalued-127-200747807.html
What is HC Wainwright's Estimate for VIR FY2026 Earnings?
November 11 at 7:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-what-is-hc-wainwrights-estimate-for-vir-fy2026-earnings-2026-11-11/
Vir Biotechnology (NASDAQ:VIR) Earns "Buy" Rating from HC Wainwright
November 11 at 1:31 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31190883
Vir Biotechnology’s hepatitis D drug scores in Phase II and Phase III trials
November 10 at 2:54 PM  |  msn.comhttps://www.msn.com/en-us/news/other/vir-biotechnology-s-hepatitis-d-drug-scores-in-phase-ii-and-phase-iii-trials/ar-AA2h9Yh2
Is Vir Biotechnology (VIR) A Bargain After Its Hepatitis Delta Phase 3 Win?
November 10 at 2:54 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vir-biotechnology-vir-bargain-hepatitis-031200167.html
Vir Biotechnology (NASDAQ:VIR) Stock Gets Price Target Bump from Morgan Stanley
November 10 at 12:35 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-vir-biotechnology-nasdaq-vir-stock-gets-price-target-bump-from-morgan-stanley-2026-11-10/
Vir Biotechnology Hepatitis Delta Treatment Meets Phase III Goals, With 79% Virus-Free at Week 48
November 10 at 9:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-vir-biotechnology-hepatitis-delta-treatment-meets-phase-iii-goals-with-79-virus-free-at-week-48-2026-11-10/
Vir Biotechnology, Inc. (VIR) Discusses ECLIPSE 1 Topline Results and Expanded SOLSTICE Data - Slideshow
November 10 at 8:34 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4965722-vir-biotechnology-inc-vir-discusses-eclipse-1-topline-results-and-expanded-solstice-data
Vir Biotechnology: Fairly Valued After Phase 3 Success?
November 10 at 8:15 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4965664-vir-biotechnology-stock-fairly-valued-after-phase-3-success
Vir, a Gilead rival, shoots to two-year high on its clean win in hepatitis D treatment
November 9 at 7:43 PM  |  msn.comhttps://www.msn.com/en-us/news/other/vir-a-gilead-rival-shoots-to-two-year-high-on-its-clean-win-in-hepatitis-d-treatment/ar-AA2h50iC
Vir Biotechnology (VIR) Says Its Hepatitis Delta Therapy Met All Phase 3 Endpoints
November 9 at 7:43 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vir-biotechnology-vir-says-hepatitis-191317265.html
Vir Biotechnology, Inc. (VIR) Discusses ECLIPSE 1 Topline Results and Expanded SOLSTICE Data Transcript
November 9 at 3:00 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4965072-vir-biotechnology-inc-vir-discusses-eclipse-1-topline-results-and-expanded-solstice-data
Vir Biotechnology Stock Jumps 14%
November 9 at 2:42 PM  |  rttnews.comhttps://www.rttnews.com/3711970/vir-biotechnology-stock-jumps-14.aspx
HC Wainwright Reaffirms "Buy" Rating for Vir Biotechnology (NASDAQ:VIR)
November 9 at 11:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-hc-wainwright-reaffirms-buy-rating-for-vir-biotechnology-nasdaq-vir-2026-11-09/
Vir Biotechnology (NASDAQ:VIR) Shares Gap Up - Time to Buy?
November 9 at 10:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vir-biotechnology-nasdaq-vir-shares-gap-up-time-to-buy-2026-11-09/
Vir Biotechnology's Hepatitis Delta Combo Meets Primary Endpoint in Phase 3 Trial; Shares Jump in Premarket
November 9 at 9:41 AM  |  marketscreener.comM
VIR stock soars over 10% overnight, eyes best year ever — hepatitis win sparks buyout buzz and bigger bullish bets
November 9 at 9:41 AM  |  msn.comhttps://www.msn.com/en-in/news/other/vir-stock-soars-over-10-overnight-eyes-best-year-ever-hepatitis-win-sparks-buyout-buzz-and-bigger-bullish-bets/ar-AA2h364T
Vir's Hepatitis Delta Combo Shows Sustained Viral Suppression; Shares Rise 15% Premarket
November 9 at 9:41 AM  |  rttnews.comhttps://www.rttnews.com/3711716/vir-s-hepatitis-delta-combo-shows-sustained-viral-suppression-shares-rise-15-premarket.aspx
Vir Biotechnology's Hepatitis Delta Combo Meets Primary Endpoint in Phase 3 Trial; Shares Rise Pre-Bell
November 9 at 9:41 AM  |  marketscreener.comM
Vir Biotechnology Stock Gains on Positive Trial Results for Chronic Hepatitis Treatment
November 9 at 9:41 AM  |  marketwatch.comhttps://www.marketwatch.com/story/vir-biotechnology-stock-gains-on-positive-trial-results-for-chronic-hepatitis-treatment-54925ed5
Vir Stock Soars After Late-Stage Trial Win. Why Biotech Could Be Headed for the FDA
November 9 at 9:41 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vir-stock-soars-stage-trial-134528846.html
Vir Biotechnology Shares Rise 22% as Phase 3 Hepatitis Delta Trial Meets Primary and Secondary Endpoints
November 9 at 9:41 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vir-biotechnology-shares-rise-22-135600627.html
Vir Biotechnology reports positive hepatitis results, early signs of possible cure
November 8 at 11:36 PM  |  msn.comhttps://www.msn.com/en-us/news/other/vir-biotechnology-reports-positive-hepatitis-results-early-signs-of-possible-cure/ar-AA2h1eSs
Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and ...
November 8 at 6:36 PM  |  marketscreener.comM
Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data
November 8 at 5:00 PM  |  businesswire.comhttps://www.businesswire.com/news/home/20261108600446/en/Vir-Biotechnology-Announces-Expanded-Phase-2-SOLSTICE-Data-for-Elebsiran-and-Tobevibart-in-Chronic-Hepatitis-Delta-Showing-Deep-and-Sustained-Viral-Suppression-and-Exploratory-Finite-Treatment-Data/
Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta
November 8 at 4:15 PM  |  businesswire.comhttps://www.businesswire.com/news/home/20261108631000/en/vir-biotechnology-announces-primary-endpoint-met-in-pivotal-phase-3-eclipse-1-trial-for-elebsiran-and-tobevibart-in-chronic-hepatitis-delta/
Vir Biotechnology (NASDAQ:VIR) Price Target Raised to $20.00
November 8 at 3:04 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31185486
Vir Biotechnology (NASDAQ:VIR) Hits New 1-Year High on Analyst Upgrade
November 8 at 1:41 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31185025
Vir Biotechnology Announces Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta
November 7, 2026  |  marketscreener.comM
Vir Biotechnology Stock Gets Focus As Phase 3 Hepatitis Delta Data Head To AASLD
November 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vir-biotechnology-stock-gets-focus-151533458.html
Vir Biotechnology (NASDAQ:VIR) Shares Cross Above 50 Day Moving Average - Should You Sell?
November 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vir-biotechnology-nasdaq-vir-shares-cross-above-50-day-moving-average-should-you-sell-2026-11-07/
Vir Biotechnology (NASDAQ:VIR) Stock Lifted to Buy by Wall Street Zen
November 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31183492
Vir Biotechnology (NASDAQ:VIR) Upgraded at Wall Street Zen
November 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-vir-biotechnology-nasdaq-vir-upgraded-at-wall-street-zen-2026-11-07/
Vir Biotechnology, Inc. Q3 2026 Earnings Call Summary
November 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vir-biotechnology-inc-q3-2026-133000362.html
Vir Biotechnology (NASDAQ:VIR) Hits New 52-Week High on Analyst Upgrade
November 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vir-biotechnology-nasdaq-vir-hits-new-52-week-high-on-analyst-upgrade-2026-11-06/
Vir Biotechnology (NASDAQ:VIR) Stock Rating Upgraded by Zacks Research
November 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-vir-biotechnology-nasdaq-vir-stock-rating-upgraded-by-zacks-research-2026-11-06/
Vir Bio (VIR) Q3 2026 Earnings Call Transcript
November 5, 2026  |  fool.comhttps://www.fool.com/earnings/call-transcripts/2026/11/05/vir-bio-vir-q3-2026-earnings-call-transcript/
Needham & Company LLC Issues Positive Forecast for Vir Biotechnology (NASDAQ:VIR) Stock Price
November 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-needham-company-llc-issues-positive-forecast-for-vir-biotechnology-nasdaq-vir-stock-price-2026-11-05/
Vir Biotechnology (NASDAQ:VIR) EVP Sells $15,216.19 in Stock
November 5, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-vir-insider-buying-and-selling-2026-11-05/
What Vir Biotechnology (VIR) Said on Its Q3 Earnings Call
November 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/transcript-what-vir-biotechnology-vir-said-on-its-q3-earnings-call-2026-11-05/
Transcript : Vir Biotechnology, Inc., Q3 2026 Earnings Call, Nov 04, 2026
November 5, 2026  |  marketscreener.comM
Vir projects cash runway into 2H 2028 as it expects ECLIPSE-1 top line data in Q3 2026
November 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4666156-vir-projects-cash-runway-into-2h-2028-as-it-expects-eclipseminus-1-top-line-data-in-q3-2026
Vir Biotechnology, Inc. (VIR) Q3 2026 Earnings Call Transcript
November 4, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4962701-vir-biotechnology-inc-vir-q3-2026-earnings-call-transcript
Vir Biotechnology Q3 2026: EPS Beat Masks Negative Revenue Ahead of ECLIPSE 1
November 4, 2026  |  247wallst.comhttps://247wallst.com/cards/vir-biotechnology-q3-2026-earnings-vir-01m6m7vawvfr6bh2613f46wjth
Vir Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026
November 4, 2026  |  marketscreener.comM
Vir Biotechnology (NASDAQ:VIR) Releases Quarterly Earnings Results, Beats Expectations By $0.18 EPS
November 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/earnings-vir-biotechnology-nasdaq-vir-releases-quarterly-earnings-results-beats-expectations-by-018-eps-2026-11-04/
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results
November 4, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261104025803/en/vir-biotechnology-provides-corporate-update-and-reports-third-quarter-2026-financial-results/
Insider Selling: Vir Biotechnology (NASDAQ:VIR) EVP Sells $15,216.19 in Stock
November 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-vir-biotechnology-nasdaq-vir-evp-sells-1521619-in-stock-2026-11-04/
Vir Biotechnology (NASDAQ:VIR) EVP Sells $26,717.70 in Stock
November 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-vir-biotechnology-nasdaq-vir-evp-sells-2671770-in-stock-2026-11-04/
Vir Biotechnology (VIR) Projected to Announce Earnings on Wednesday
November 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31175788

Vir Biotechnology Media Mentions By Week

Vir Biotechnology Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

VIR
News Sentiment
▼
0.52

0.57
▲
Average
Healthcare
News Sentiment

Vir Biotechnology News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

VIR Articles
This Week
▼
64

6
▲
VIR Articles
Average Week

Vir Biotechnology Trends on MarketBeat

This week vs. last week
New Followers
1
Searches
2
+100%
Page Views
1,862
-39%
Get Vir Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools

Related Companies
News and Trends Tools

MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Vir Biotechnology dated 11/11/2026.
From Our Partners
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
The Withdrawal You'll Never See on Your Statement
A proposal circulating in Washington, dubbed the Mar-a-Lago Accord, calls for tariffs and currency pressure to...
Bishop Gold Group | Sponsoredtc pixel
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...
Behind the Markets | Sponsoredtc pixel
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...
Weiss Ratings | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel